Silexion Therapeutics Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.6M
- Price
- $0.254
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.35%
- Volume
- 918.1K
About
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Quick stats
Shares outstanding14.3M
Computed float12.3M
Float / shares86.0%
Cash runway (months)2.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002022416
Websitehttps://silexion.com
AI Summary
AI-generated1/16
standardbullishclinical trial
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics dosed the first patient worldwide in its Phase 2/3 trial of lead RNAi candidate SIL204 in locally advanced pancreatic cancer, treated at Tel Aviv Sourasky Medical Center in Israel.
The trial combines a safety run-in of about 18 patients with a randomized expansion of about 166 patients, testing SIL204 plus standard chemotherapy versus chemotherapy alone in newly diagnosed, KRAS-mutated Stage 3 LAPC patients.
SIL204 uses a dual-route delivery strategy: EUS-guided intratumoral injection to penetrate tumor stroma plus subcutaneous dosing for systemic exposure, with additional sites in Israel and Germany expected to activate in coming months.
Red flags
- preliminary clinical readouts promised 'in the near term' carry execution and data risk
- company flags future capital requirements and need for additional financing to fund trials
- open-label trial design may complicate interpretation of efficacy signals